European Penny Stocks Under €200M Market Cap: 3 Promising Picks

The European market has recently experienced a dip, with the pan-European STOXX Europe 600 Index ending the week down amid global bond sell-offs and inflationary pressures. Despite these challenges, certain investment opportunities remain attractive, particularly in niche areas like penny stocks. Although the term "penny stocks" may seem outdated, these smaller or newer companies can offer significant growth potential when supported by strong financial health.

Let's review some notable picks from our screened stocks.

Nanoform Finland Oyj (HLSE:NANOFH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Nanoform Finland Oyj provides nanotechnology and drug particle engineering services to the pharma and biotech industries in Europe and the United States, with a market cap of €85.15 million.

Operations: The company generates its revenue of €5.53 million from offering Nanoforming, Formulation, and Analytical Services.

Market Cap: €85.15M

Nanoform Finland Oyj, with a market cap of €85.15 million, is navigating the penny stock landscape with its focus on nanotechnology and drug particle engineering. Despite being unprofitable and not expected to achieve profitability in the near term, it has managed to reduce losses over recent years. The company reported second-quarter sales of €0.775 million, up from €0.667 million a year ago, while net loss decreased significantly from €5.96 million to €3.73 million year-over-year. With short-term assets exceeding liabilities and a seasoned management team, Nanoform maintains financial stability despite high share price volatility and negative return on equity.

• Jump into the full analysis health report here for a deeper understanding of Nanoform Finland Oyj.
• Examine Nanoform Finland Oyj's earnings growth report to understand how analysts expect it to perform.

Arbona (NGM:ARBO A)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Arbona AB (publ) is a company that invests in small and medium-sized listed companies in Sweden, with a market cap of SEK1.77 billion.

Operations: Arbona AB (publ) has not reported any specific revenue segments.

Market Cap: SEK1.77B

Arbona AB (publ), with a market cap of SEK1.77 billion, operates in the penny stock arena by investing in small to medium-sized companies. Recent earnings showed revenue growth to SEK 571.81 million for the half year ended June 30, 2026, up from SEK 477.59 million a year prior, and net income increased to SEK 69.44 million from SEK 60.87 million despite lower profit margins due to large one-off gains impacting results. The company’s strong liquidity is highlighted by short-term assets exceeding both short and long-term liabilities, while its debt is well covered by operating cash flow and cash reserves exceed total debt levels.

• Get an in-depth perspective on Arbona's performance by reading our balance sheet health report here.
• Examine Arbona's past performance report to understand how it has performed in prior years.

Sprint Bioscience (OM:SPRINT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Sprint Bioscience AB (publ) is a Swedish pharmaceutical company focused on developing drug candidates for cancer treatment, with a market cap of SEK347.15 million.

Operations: Sprint Bioscience AB (publ) has not reported any specific revenue segments.

Market Cap: SEK347.15M

Sprint Bioscience AB, with a market cap of SEK347.15 million, has recently transitioned to profitability, marking a significant milestone in its financial journey. Despite this achievement, the company remains pre-revenue with minimal reported earnings and a substantial net loss for the recent quarter. The stock's high volatility is notable but has decreased over the past year. Sprint Bioscience's strategic alliance with Lilly TuneLab aims to enhance its drug discovery capabilities using AI and machine learning, potentially accelerating preclinical programs. Its short-term assets significantly exceed liabilities, providing some financial stability despite ongoing challenges in revenue generation.

• Take a closer look at Sprint Bioscience's potential here in our financial health report.
• Assess Sprint Bioscience's future earnings estimates with our detailed growth reports.

Taking Advantage

• Gain an insight into the universe of 309 European Penny Stocks by clicking here.
• Ready To Venture Into Other Investment Styles? We've found 7 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com